Regeneron Pharmaceuticals
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1988-01-01
- Employees
- 13.4K
- Market Cap
- $132.4B
- Website
- http://www.regeneron.com
- Introduction
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.
Eye on Pharma: High Strength Trastuzumab Biosimilar; Originator Coverage Removals
FDA approves 420 mg strength of Hercessi (trastuzumab-strf) biosimilar; UnitedHealth to remove Humira from preferred drug lists in favor of biosimilars; Evernorth offers interchangeable ustekinumab biosimilar at no cost; Samsung Bioepis receives positive opinion for aflibercept biosimilar.
As 2seventy Nears Breakeven, CEO Chip Baird Explains How the Team Survived
Despite numerous challenges, 2seventy bio, formerly part of bluebird bio, remains focused on achieving profitability with its CAR T therapy Abecma. The company has undergone layoffs, pipeline reorganizations, and faced competition and FDA safety warnings. CEO Chip Baird predicts profitability next year, with potential growth strategies including acquisitions or licensing deals. The company's culture and resilience among its employees have been key to its survival.
FDA approves first-ever biologic for COPD
FDA approves dupilumab (Dupixent) as first biologic treatment for COPD in adults, showing 30-34% reduction in moderate or severe exacerbations in phase 3 trials BOREAS and NOTUS. Dupilumab, an IL-4 and IL-13 pathway inhibitor, is indicated for inadequately controlled COPD with eosinophilic phenotype.
Dupixent Gets FDA Approval for COPD
FDA approves Dupixent for COPD, offering a new biologic treatment option for 300,000 U.S. adults with inadequately controlled COPD and eosinophilic COPD. Dupixent, a monoclonal antibody, reduces flare-ups, improves lung function, and enhances quality of life. Common side effects include injection-site reactions and viral infections.
FDA approves Dupixent for chronic obstructive pulmonary disease
FDA approves Regeneron's Dupixent for COPD with eosinophilic phenotype, showing reduced exacerbations and improved lung function in Phase III trials.
With $115M more, Triveni accelerates immune drug work
Triveni Bio raised $115M in Series B funding to develop antibody drugs for inflammatory diseases, with its lead candidate TRIV-509 targeting atopic dermatitis. The company aims to file for FDA approval for its first trial early next year, leveraging 'best-in-class antibody design' and genetic data to differentiate its therapies from competitors like Dupixent.
FDA Approves Dupixent for Chronic Obstructive Pulmonary Disease
The FDA approved Dupixent as an add-on treatment for adults with inadequately controlled COPD and an eosinophilic phenotype, based on phase 3 trials showing a reduction in COPD exacerbations and improved lung function. Dupixent, developed by Regeneron, offers new hope for COPD patients.
DPHARM 2024 Highlights ClinOps Innovations That Address Cost Complexity Capabilities
DPHARM 2024 focused on innovations in clinical trials, featuring keynotes on ROI, DCTs, AI, and patient perspectives. Panels discussed efficiency, AI use, and ecosystem approaches. Outside-industry speakers offered unique insights. Technologists showcased patient-centric services. Sponsors highlighted innovation and collaboration. DPHARM Idol Disrupt finalists presented disruptive technologies, with Power winning for its patient-matching platform. The event aimed to improve clinical trials for faster, more efficient medicine delivery.
Breakthrough Therapy Designation Market is expected to Double
Breakthrough Therapy Designation Market to double by 2032, driven by 13.5% CAGR, fueled by pharmaceutical companies seeking faster FDA approval for serious condition treatments. Key players include AbbVie, Amgen, AstraZeneca, and others. Market challenges include high clinical trial costs and stringent regulatory requirements.
© Copyright 2024. All Rights Reserved by MedPath